ATC code none PubChem CID 11554427 UNII LJ8U884TM5 | CAS Number 869901-69-9 ChemSpider 25058456 Molar mass 461.87 g/mol | |
 | ||
Legal status US: Investigational New Drug | ||
MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection. It is superior to the first available integrase inhibitor, raltegravir, in that it inhibits the HIV enzyme integrase 4 times longer. It is being investigated for use as part of pre-exposure prophylaxis (PrEP).
It is being developed by Merck & Co.
References
MK-2048 Wikipedia(Text) CC BY-SA